{"version":"1.0","type":"link","title":"A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.","author_name":"Rosenberg AJ 외","author_url":"https://prs-insight.online/author/Rosenberg%20AJ","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/145456","thumbnail_width":1200,"thumbnail_height":630}